Magnetic resonance-guided prostate interventions

Topics in Magnetic Resonance Imaging

Volumn 16, Issue 5, 2005, Pages 355-368

  Haker, Steven J ^a   Mulkern, Robert V ^a   Roebuck, Joseph R ^a   Barnes, Agnieska Szot ^a   DiMaio, Simon ^a   Hata, Nobuhiko ^a   Tempany, Clare M C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

MR guided prostate therapy; Prostate biopsy; Prostate brachytherapy

Indexed keywords

BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER THERAPY; CONTRAST ENHANCEMENT; HUMAN; IMAGE PROCESSING; INTERVENTIONAL RADIOLOGY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; REVIEW; ROBOTICS;

EID: 33748059236     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002142-200510000-00003     Document Type: Review

References (115)

1. Cancer facts and figures 2004. Atlanta GA: American Cancer Society; 2004.
2. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-1451.
3. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167:528-534.
4. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523.
5. Comet-Batlle J, Vilanova-Busquets JC, Saladie-Roig JM, et al. The value of endorectal MRI in the early diagnosis of prostate cancer. Eur Urol. 2003 Aug;44:201-207.
6. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology. 1994;193:703-709.
7. Barentsz JO, Engelbrecht M, Jager GJ, et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging. 1999;10:295-304.
8. Huisman HJ, Engelbrecht MR, Barentsz JO. Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging. 2001;13:607-614.
9. Futterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology. 2005;237:541-549.
10. Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology. 2003 Oct;229:248-254.
11. Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol. 2003 Dec;170:S69-S75.
12. Presti JC Jr. Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy. Radiol Clin North Am. 2000;38:49-58.
13. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North AM. 2000;38:59-85.
14. Kurhanewicz J, Swanson MG, Nelson SJ, et al. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imag. 2002;16:451-463.
15. Yu KK, Hricak H, Alagappan R, et al. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology. 1997;202:697-702.
16. Kurhanewicz J, Vigneron DB, Males RG, et al. The prostate: MR imaging and spectroscopy. Present and Future. Radiol Clin North Am. 2000;38:115-138.
17. May F, Treumann T, Dettmar P, et al. Limited value of endorectal magnetic resonance imaging and transrectal ultra-sonography in the staging of clinically localized prostate cancer. BJU Int. 2001;87:66-69.
18. D'Amico AV, Whittington R, Malcowicz SB, et al. Critical analysis of the ability of endorectal coil magnetic resonance imaging to predict pathological stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol. 1996;14:1770.
19. D'Amico AV, Whittington R, Schnall M, et al. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic prostate cancer. Cancer. 1995;75:2368.
20. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased array coils. Radiology. 1994;193:703-709.
21. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002;223:91-97.
22. Jager GJ, Rijter ETG, van da Kaa C, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol. 1996;166:845-852.
23. Tempany CM, Zhou X, Zerhouni EA, et al. Staging of prostate cancer: results of radiology oncology group project comparison of three MR imaging techniques. Radiology. 1994;192:47.
24. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology. 1995;195:385-390.
25. Schiebler ML, Schnall MD, Pollack HM, et al. Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology. 1993;189:339-352.
26. Grossfeld GD, Coakley FV. Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. Radiol Clin North Am. 2000;38:31-47.
27. Ling D, Lee JK, Heiken JP, et al. Prostatic carcinoma and benign prostatic hyperplasia: inability of MR imaging to distinguish between the two diseases. Radiology. 1986;158:103.
28. Futterer JJ, Scheenen TW, Huisman HJ, et al. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol. 2004;39:671-680.
29. van Dorsten FA, van der Graaf M, Engelbrecht MRW, et al. Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imag. 2004;20:279-287.
30. Kurhanewicz J, Vigneron DB, Hricak H, et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996;198:795-805.
31. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology. 1999;213:473-480.
32. Mulkern RV, Bowers JL. Calculating spectral modulations of AB systems during PRESS acquisitions. Magn Reson Med. 1993;30:518-519.
33. Mulkern RV, Bowers JL. Density matrix calculations of AB spectral modulations: quantum mechanics meets in vivo spectroscopy. Concepts Magn Reson. 1994;6:1-23.
34. Mulkern RV, Bowers JL, Peled S, et al. Citrate signal enhancement with a homonuclear J-refocusing modification to double-echo PRESS sequences. Magn Reson Med. 1996;36:775-780.
35. Brown TR, Kincaid BM, Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci U S A. 1982;179:3523-2526.
36. Maudsley AA, Hilal SK, Perman WH, et al. Spatially resolved high-resolution spectroscopy by "four-dimensional". NMR J Magn Reson. 1983;51:147-152.
37. Vigneron D, Males R, Hricak H, et al. Prostate cancer: correlation of 3D MRSI metabolite levels with histologic grade. Paper presented at: Proceedings of Radiological Society of North America; 1998; Chicago, IL.
38. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804-814.
39. Choi H, Zhou XJ, Ma J. Use of perfluorocarbon (PFC) in magnetic resonance spectroscopy (MRS) of prostate: a method to improve the linewidth and quality of spectra. Book of Abstracts, RSNA. 2004:270.
40. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI and 3D MRSI. Magn Reson Med. 2005;53:249-255.
41. Ito H, Kamoi K, Yokoyama K, Yamada K, Nishimura T. Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. Br J Radiol. 2003;76:617-624.
42. Preziosi P, Orlacchio A, Di Giambattista G, et al. Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol. 2003;13:925-930.
43. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumor stage, histological grade and PSA. Clin Radiol. 2000;55:99-109.
44. Turnbull LW, Buckley DL, Turnbull LS, et al. Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA enhanced MR imaging and histopathology. J Magn Reson Imaging. 1999;9:311-316.
45. Koroshetz WJ, Gonzalez G. Diffusion-weighted MRI: an ECG for "brain attack". Ann Neurol. 1997;41:565-566.
46. Lutsep HL, Albers GW, DeCrespigny A, et al. Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke. Ann Neurol. 1997;41:574-580.
47. Stejskal EO, Tanner JE. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys. 1965;42:288-292.
48. Turner R, Le Bihan D, Chesnick AS. Echo-planar imaging of diffusion and perfusion. Magn Reson Med. 1991;19:247-253.
49. Hosseinzadeh K, Schwarz SD. Endo-rectal diffusion weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004:654-661.
50. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging. 2002;16:196-200.
51. Gibbs P, Tozer DJ, Liney GP, et al. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-1058.
52. Chan I, Wells W III, Mulkern RV, et al. Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted MR imaging; a multi-channel statistical classifier. Med Phys. 2003;30:2390-2398.
53. Gudbjartsson H, Maier SE, Mulkern RV, et al. Line scan diffusion imaging. Magn Reson Med. 1996;36:509-518.
54. Kooy HM, Cormack RA, Mathiowitz G, et al. A software system for interventional magnetic resonance image-guided prostate brachytherapy. Comput Aided Surg. 2000;5:401-413.
55. Cline HE, Hynynen K, Hardy CJ, et al. MR temperature mapping of focused ultrasound surgery. Magn Reson Med. 1994;31:628-636.
56. Jolesz FA, Hynynen K. Magnetic resonance image-guided focused ultrasound surgery. Cancer J. 2002;8(suppl 1):S100-S112.
57. Hynynen K, Darkazanli A, Damianou CA, et al. Tissue thermometry during ultrasound exposure. Eur Urol. 1993;23(suppl 1):12-16.
58. Jolesz FA, Nabavi A, Kikinis R. Integration of interventional MRI with computer-assisted surgery. J Magn Reson Imaging. 2001;13:69-77.
59. Fry WJ, Barnard JW, Fry FJ, et al. Ultrasonic lesions in mammalian central nervous system. Science. 1955;122:517.
60. Hynynen K, Pomeroy O, Smith DN, et al. MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: a feasibility study. Radiology. 2001;219:176-185.
61. Huber PE, Jenne JW, Rastert R, et al. A new noninvasive approach in breast cancer therapy using magnetic resonance imaging-guided focused ultrasound surgery. Cancer Res. 2001;61:8441-8447.
62. Tempany CM, Stewart EA, McDannold N, et al. MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology. 2003;226:897-905.
63. The American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
64. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71.
65. Presti JC Jr, Chang JJ, Bhargava V, et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsy cores: results of a prospective clinical trial. J Urol. 2000;163:163-166.
66. Terris MK, Wallen EM, Stamey TA. Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int. 1997;59:239-242.
67. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol. 2002;168:922-925.
68. Norberg M, Egevad L, Holmberg L, et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997;50:562-566.
69. Rabbani R, Stroumbakis N, Kava BR. Incidence and clinical significance of false negative sextant prostate biopsies. J Urol. 1998;159:1247.
70. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000;164:400-404.
71. Terris MK, McNeal JE, Freiha FS, et al. Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J Urol. 1993;149:1035-1039.
72. Keetch DW, McMurtry JM, Smith DS, et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol. 1996;156:428-431.
73. Epstein JI, Walsh PC, Sauvagerot J, et al. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol. 1997;158:1886.
74. Stroumbakis N, Cookson MS, Reuter VE, et al. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology Suppl. 1997;49:113.
75. Gore JL, Shariat SF, Miles BJ, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001;165:1554-1559.
76. Stewart CS, Leibovich BC, Weaver AL, et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166:86-92.
77. Perrotti M, Han KR, Epstein RE, et al. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study. J Urol. 1999;162:1314-1317.
78. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242-248.
79. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71(3 suppl):933-938.
80. Hata N, Jinzaki M, Kacher D, et al. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology. 2001;220:263-268.
81. Cormack RA, D'Amico AV, Hata N, et al. Feasibility of transperineal prostate biopsy under interventional MR guidance. Urology. 2000;56:663-664.
82. D'Amico AV, Tempany CM, Cormack R, et al. Transperineal magnetic resonance image guided prostate biopsy. J Urol. 2000;164:385-387.
83. Warfield SK, Haker SJ, Talos IF, et al. Capturing intraoperative deformations: research experience at Brigham and Women's Hospital. Med Image Anal. 2005;9:145-162.
84. Hirose M, Bharatha A, Hata N, et al. Quantitative MR imaging assessment of prostate gland deformation before and during MR imaging-guided brachytherapy. Acad Radiol. 2002;9, 8:906-912.
85. Bharatha A, Hirose M, Hata N, et al. Evaluation of three-dimensional finite element-based deformable registration of pre- and intra-operative prostate imaging. Med Phys. 2001;28:2551-2560.
86. Haker S, Warfield SK, Tempany CMC. Landmark-guided surface matching and volumetric warping for improved prostate biopsy targeting and guidance, MICCAI 2004. Presented at: 7th International Conference; September 26-29, 2004; Saint-Malo, France, pp. 853-861.
87. Ferrant M, Warfield SK, Nabavi A, et al. Registration of 3d intraoperative MR images of the brain using a finite element biomechanical model. Presented at; Third International Conference on Medical Image Computing and Computer-assisted Intervention; 2002; Pittsburgh, PA.
88. Shen D, Lao Z, Zeng J, et al. A statistical atlas of prostate cancer for optimal biopsy. Lecture Notes in Computer Science. Jan 2001;2208:416.
89. Shen D, Lao Z, Herskovits EH, et al. Statistically Optimized Biopsy Strategy for the Diagnosis of Prostate Cancer. Presented at: 14th IEEE Symposium on Computer-Based Medical Systems (CMBS'01); 2001; p. 433.
90. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol. 2000;4:233-241.
91. D'Amico AV, Tempany CM, Schultz D, et al. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology. 2003;62:1063-1067.
92. D'Amico AV, Tempany CM, Schultz D, et al. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology. 2003;62:1063-1067.
93. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
94. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517-522.
95. Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261-1266.
96. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81-94.
97. Merrick GS, Wallner K, Butler WM, et al. Short-term sexual function after prostate brachytherapy. Int J Cancer. 2001;96:313-319.
98. Beyer DC. The evolving role of prostate brachytherapy. Cancer Control. 2001;8:163-170.
99. Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys. 2000;47:129-136.
100. Lee WR, Hall MC, McQuellon RP, et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:614-623.
101. Zelefsky MJ,-amada Y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:956-963.
102. King CR, DiPetrillo TA, Wazer DE. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys. 2000;46:165-172.
103. Talcott JA, Clark JA, Stark PC, et al. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol. 2001;166:494-499.
104. Merrick GS, Butler WM, Dorsey AT, et al. Rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:667-674.
105. Krumholtz JS, Michalski JM, Sundaram CP. Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer. J Endourol. 2000;14:371-374.
106. Alexianu M, Weiss GH. Radical prostatectomy versus brachytherapy for early-stage prostate cancer. J Endourol. 2000;14:325-328.
107. Chan AJ, Saltzman B. Role of brachytherapy in patients with stage T1c, T2a adenocarcinoma of the prostate. J Endourol. 2000;14:319-324.
108. D'Amico AV, Cormack R, Kumar S, et al. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. J Endourol. 2000;14:367-370.
109. Thomas MD, Cormack R, Tempany CM, et al. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:905-908.
110. Albert M, Tempany CM, Schultz D, et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer. 2003;98:949-954.
111. Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001;39:1118-1130.
112. Chinzei K, Kikinis R, Jolesz FA. MR compatibility of mechatronic devices: design criteria. In: Medical Image Computing and 'Computer-assisted Intervention - Miccai '99. 1999;1679:1020-1030.
113. Chinzei K, Hata N, Jolesz FA, et al. MR compatible surgical assist robot: system integration and preliminary feasibility study. In: Medical Image Computing and Computer-assisted Intervention - Miccai 2000. 2000;1935:921-930.
114. Chinzei K, Miller K. Towards MRI guided surgical manipulator. Med Sci Monit. 2001;7:153-163.
115. DiMaio SP, Pieper S, Chinzei K, et al. Robot assisted percutaneous intervention in open-MRI. Presented at: 5th Interventional MRI Symposium; October 15-16; Boston, MA; 2004. p. 155.